{"id":6926,"date":"2021-10-28T11:20:39","date_gmt":"2021-10-28T09:20:39","guid":{"rendered":"http:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Axial_AB2004-IND-Clearance-Press-Release-2021OCT26_V04-Final-.pdf"},"modified":"2021-10-28T11:20:39","modified_gmt":"2021-10-28T09:20:39","slug":"axial_ab2004-ind-clearance-press-release-2021oct26_v04-final","status":"inherit","type":"attachment","link":"https:\/\/www.seventure.fr\/en\/axial-therapeutics-receives-fda-clearance-of-ind-application-and-initiates-phase-2b-trial-for-ab-2004-lead-gut-targeted-molecular-therapeutic-for-the-treatment-of-irritability-in-autism-spectrum-dis\/axial_ab2004-ind-clearance-press-release-2021oct26_v04-final\/","title":{"rendered":"Axial_AB2004 IND Clearance Press Release 2021OCT26_V04 Final"},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false},"class_list":["post-6926","attachment","type-attachment","status-inherit","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v25.2 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Axial_AB2004 IND Clearance Press Release 2021OCT26_V04 Final | Seventure<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Axial_AB2004-IND-Clearance-Press-Release-2021OCT26_V04-Final-.pdf\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Axial_AB2004-IND-Clearance-Press-Release-2021OCT26_V04-Final-.pdf\",\"url\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Axial_AB2004-IND-Clearance-Press-Release-2021OCT26_V04-Final-.pdf\",\"name\":\"Axial_AB2004 IND Clearance Press Release 2021OCT26_V04 Final | Seventure\",\"isPartOf\":{\"@id\":\"https:\/\/www.seventure.fr\/en\/#website\"},\"datePublished\":\"2021-10-28T09:20:39+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Axial_AB2004-IND-Clearance-Press-Release-2021OCT26_V04-Final-.pdf#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Axial_AB2004-IND-Clearance-Press-Release-2021OCT26_V04-Final-.pdf\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Axial_AB2004-IND-Clearance-Press-Release-2021OCT26_V04-Final-.pdf#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.seventure.fr\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Axial Therapeutics Receives FDA Clearance of IND Application and Initiates Phase 2b Trial for AB-2004, Lead Gut-Targeted, Molecular Therapeutic for the Treatment of Irritability in Autism Spectrum Disorder\",\"item\":\"https:\/\/www.seventure.fr\/en\/axial-therapeutics-receives-fda-clearance-of-ind-application-and-initiates-phase-2b-trial-for-ab-2004-lead-gut-targeted-molecular-therapeutic-for-the-treatment-of-irritability-in-autism-spectrum-dis\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Axial_AB2004 IND Clearance Press Release 2021OCT26_V04 Final\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.seventure.fr\/en\/#website\",\"url\":\"https:\/\/www.seventure.fr\/en\/\",\"name\":\"Seventure\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.seventure.fr\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Axial_AB2004 IND Clearance Press Release 2021OCT26_V04 Final | Seventure","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Axial_AB2004-IND-Clearance-Press-Release-2021OCT26_V04-Final-.pdf","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Axial_AB2004-IND-Clearance-Press-Release-2021OCT26_V04-Final-.pdf","url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Axial_AB2004-IND-Clearance-Press-Release-2021OCT26_V04-Final-.pdf","name":"Axial_AB2004 IND Clearance Press Release 2021OCT26_V04 Final | Seventure","isPartOf":{"@id":"https:\/\/www.seventure.fr\/en\/#website"},"datePublished":"2021-10-28T09:20:39+00:00","breadcrumb":{"@id":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Axial_AB2004-IND-Clearance-Press-Release-2021OCT26_V04-Final-.pdf#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Axial_AB2004-IND-Clearance-Press-Release-2021OCT26_V04-Final-.pdf"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Axial_AB2004-IND-Clearance-Press-Release-2021OCT26_V04-Final-.pdf#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.seventure.fr\/en\/"},{"@type":"ListItem","position":2,"name":"Axial Therapeutics Receives FDA Clearance of IND Application and Initiates Phase 2b Trial for AB-2004, Lead Gut-Targeted, Molecular Therapeutic for the Treatment of Irritability in Autism Spectrum Disorder","item":"https:\/\/www.seventure.fr\/en\/axial-therapeutics-receives-fda-clearance-of-ind-application-and-initiates-phase-2b-trial-for-ab-2004-lead-gut-targeted-molecular-therapeutic-for-the-treatment-of-irritability-in-autism-spectrum-dis\/"},{"@type":"ListItem","position":3,"name":"Axial_AB2004 IND Clearance Press Release 2021OCT26_V04 Final"}]},{"@type":"WebSite","@id":"https:\/\/www.seventure.fr\/en\/#website","url":"https:\/\/www.seventure.fr\/en\/","name":"Seventure","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.seventure.fr\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"description":{"rendered":"<p class=\"attachment\"><a href='https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Axial_AB2004-IND-Clearance-Press-Release-2021OCT26_V04-Final-.pdf'><img loading=\"lazy\" decoding=\"async\" width=\"232\" height=\"300\" src=\"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Axial_AB2004-IND-Clearance-Press-Release-2021OCT26_V04-Final-pdf-232x300.jpg\" class=\"attachment-medium size-medium\" alt=\"\" \/><\/a><\/p>\n"},"caption":{"rendered":""},"alt_text":"","media_type":"file","mime_type":"application\/pdf","media_details":{"sizes":{"thumbnail":{"file":"Axial_AB2004-IND-Clearance-Press-Release-2021OCT26_V04-Final-pdf-116x150.jpg","width":116,"height":150,"mime_type":"image\/jpeg","source_url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Axial_AB2004-IND-Clearance-Press-Release-2021OCT26_V04-Final-pdf-116x150.jpg"},"medium":{"file":"Axial_AB2004-IND-Clearance-Press-Release-2021OCT26_V04-Final-pdf-232x300.jpg","width":232,"height":300,"mime_type":"image\/jpeg","source_url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Axial_AB2004-IND-Clearance-Press-Release-2021OCT26_V04-Final-pdf-232x300.jpg"},"large":{"file":"Axial_AB2004-IND-Clearance-Press-Release-2021OCT26_V04-Final-pdf-791x1024.jpg","width":791,"height":1024,"mime_type":"image\/jpeg","source_url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Axial_AB2004-IND-Clearance-Press-Release-2021OCT26_V04-Final-pdf-791x1024.jpg"},"full":{"file":"Axial_AB2004-IND-Clearance-Press-Release-2021OCT26_V04-Final-pdf.jpg","width":1088,"height":1408,"mime_type":"application\/pdf","source_url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Axial_AB2004-IND-Clearance-Press-Release-2021OCT26_V04-Final-pdf.jpg"}}},"post":6925,"source_url":"https:\/\/www.seventure.fr\/wp-content\/uploads\/2021\/10\/Axial_AB2004-IND-Clearance-Press-Release-2021OCT26_V04-Final-.pdf","_links":{"self":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/media\/6926","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/media"}],"about":[{"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/types\/attachment"}],"author":[{"embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/www.seventure.fr\/en\/wp-json\/wp\/v2\/comments?post=6926"}]}}